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Background: The histologic grade of a prostate needle-core biopsy specimen can determine whether a patient with
prostate cancer is a candidate for radical prostatectomy or other treatment. Incorrect histologic grading can result
in inappropriate treatment and possible liability. Thus, we conducted this study to determine the histologic-grading
accuracy of prostate cancer needle-core biopsy specimens.
Methods: Fifty-two patients with localized prostate cancer treated with radical prostatectomy were included in the
study. The overall correlation between Gleason scores for needle-biopsy and prostatectomy specimens was evaluated
by analyzing the following parameters: biopsy-core number; accurate biopsy-core length; prostate volume; and
preoperative, serum prostate-specific antigen (PSA) level. A “downgrade” was defined as the Gleason score for the
prostatectomy specimen being greater than that for the biopsy specimen, whereas an “upgrade” was defined as
the converse.
Results: No difference in Gleason scores was noted for 31% of specimens, whereas a downgrade was noted for
40%, and an upgrade for 29%. The accuracy of Gleason scores for biopsy specimens taken by the sextant systemic-
biopsy method increased when specimens were > 15 mm in length. No correlation was noted between difference
in Gleason scores and biopsy-core number, prostate volume, and preoperative serum PSA level.
Conclusion: The accuracy of Gleason scores determined by needle biopsy in patients with prostate cancer seems
to be unreliable. Therefore, further evaluation of patients is necessary. No correlations were noted between biopsy-
measured errors in Gleason score and biopsy number, prostate volume, or preoperative serum PSA level. [J Chin
Med Assoc 2005;68(4):167–171]
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Introduction
Prostate cancer is the most commonly seen urologic
malignancy, and the histologic grade of prostate tumors
is an important determinant of disease prognosis and
survival.1,2 Although numerous grading systems exist
for the evaluation of prostate cancer, the Gleason
grading system is the most widely accepted.3 This
system is based on the glandular pattern of prostate
tumors, as identified at relatively low magnification.
Both the primary (predominant) and secondary (second
most prevalent) architectural patterns are identified
and assigned a score from 1–5, with 1 being the most
differentiated and 5 the least differentiated. The
Gleason scores of prostate biopsy specimens are used
to predict the severity of prostate cancer,4–6 and unless
prostatectomy is performed, Gleason scores are deter-
mined from such specimens.
The management of patients with localized
prostate cancer is based on clinical stage, serum
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prostate-specific antigen (PSA) level, and Gleason
score of the prostate biopsy specimen. In patients
with high Gleason-score prostate cancer, the likeli-
hood of disease recurrence increases after radical
prostatectomy.4–6 In contrast, many investigators have
suggested that patients with clinically localized, well-
differentiated or moderately differentiated prostate
cancer are not at risk of death from cancer within
10–15 years of diagnosis.7–9 Although the Gleason
score of a prostate biopsy specimen dictates the
clinical management of localized prostate cancer,
King and Long10 found that the accuracy of Gleason
scores for prostate biopsy specimens was as low as
42%. To our knowledge, the measurement of such
accuracy has never been reported in the Taiwanese
literature. Therefore, we aimed to determine whether
there was a correlation between the Gleason scores
of biopsy specimens and the need for radical pros-
tatectomy in patients with prostate cancer.
Methods
Study population
Between April 1996 and July 2002, retropubic radical
prostatectomies were performed in 65 patients with
clinically localized prostate cancer (stages cT1 and
cT2) confirmed by transrectal ultrasound-guided biop-
sy of the prostate. Prostate cancer was diagnosed in
57 patients at the China Medical University Hospital,
and in 8 patients at another institution, but all patients
underwent surgery at the former institution. Patients’
medical records and pathologic reports were reviewed.
Twelve patients were excluded from the study for the
following reasons: no detailed medical records (n = 9);
the tumor volume of biopsy-core specimens was too
small to grade (n = 2); and salvage prostatectomy had
to be performed after biochemical progression after
initially curative radiation therapy (n = 1).
Biopsy procedure and measurements
Systematic sextant biopsy, as described by Hodge et
al,11 was performed in our institution before October
2002 in 24 patients, and either the 10-core or 12-core
biopsy technique (lateral and systematic sextant biop-
sy), as described by Presti et al,12 was performed in 20
cases. An 18-gauge, automatic, spring-loaded, core-
tissue, biopsy needle (Bard® Magnum®, CR Bard Inc,
Covington, GA, USA), with a 22-mm preset length
was used for transrectal ultrasound-guided biopsy.
The biopsy and prostatectomy specimens were re-
viewed by 1 staff pathologist, and tumor grade was de-
termined according to the Gleason scoring system.3
The overall correlation between Gleason scores
for needle-biopsy and prostatectomy specimens was
evaluated by comparing the biopsy-core number,
accurate biopsy-core length, prostate volume, and
preoperative serum PSA level with Gleason scores
obtained from needle-biopsy and prostatectomy
specimens. Biopsy-core length was measured after
biopsy specimens had been fixed in 10% formalin.
Prostate volume was measured before such fixation
and was calculated by the prolate-ellipsoid volume
formula. A “downgrade” was defined as the Gleason
score for the tumor specimen from prostatectomy
being greater than that for the biopsy specimen,
whereas an “upgrade” was defined as the converse.
Statistical analyses
Values for biopsy-core number and accurate biopsy-
core length were compared by Fisher’s exact test.
Univariate analysis was used to determine the cor-
relations of prostate volume and preoperative serum
PSA level with differences in Gleason scores between
needle-biopsy and prostatectomy specimens. A p val-
ue of less than 0.05 was considered statistically signi-
ficant. All analyses were performed using SPSS ver-
sion 9.0 (SPSS Inc, Chicago, IL, USA).
Results
Demographic data
Fifty-two patients were included in the study, although
8 of them had undergone prostate biopsy at another
institution. Patient age ranged from 49–75 years
(mean, 67 years). Preoperative serum PSA level ranged
from 1.55–41.45 ng/mL (mean, 15.68 ng/mL),
and prostate volume ranged from 16.75–94.24 mL
(mean, 50.65 mL).
Gleason scores
Gleason scores ranged from 3–10 for biopsy-core
specimens, and from 3–9 for radical prostatectomy
specimens. The correlation between Gleason scores
obtained from biopsy and prostatectomy specimens is
shown in Table 1. There were no differences in Gleason
scores in 31% of specimens, but scores were down-
graded in 40% of specimens, and upgraded in 29%
(Table 2).
Gleason-score differences were examined for
possible correlation with the number of biopsy cores,
length of biopsy core, prostate volume, and serum
PSA level, among the 44 patients who underwent
biopsy and prostatectomy at our hospital (Table 3).
In sextant systemic biopsy, the accuracy of biopsy-
Gleason score from prostate biopsy
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specimen Gleason scores increased in specimens > 15
mm in length. There was no correlation between
Gleason-score difference (prostatectomy minus biop-
sy) and biopsy-core number, prostate volume, or
preoperative serum PSA level.
Gleason scores for 4 prostatectomy specimens were
3 units greater than corresponding scores for biopsy
specimens taken from the same individuals (Table 4).
Preoperative serum PSA values ranged from 5.76–
12.00 ng/mL (mean, 9.88 ng/mL), and prostate vol-
Table 1. Correlation of Gleason scores (GSs) obtained from biopsy (Bx) and radical prostatectomy (RP) specimens
GS of tumor in Bx specimen
GS of tumor in RP specimen
3 4 5 6 7 8 9 10
Total
3 2 1 3 0 0 0 0 0 6
4 1 3 3 0 3 0 0 0 10
5 0 2 3 2 3 1 0 0 11
6 0 0 1 4 0 2 0 0 7
7 0 0 2 1 2 2 0 0 7
8 0 0 0 1 2 1 2 0 6
9 0 0 0 0 3 0 1 0 4
10 0 0 0 0 0 1 0 0 1
Total 3 6 12 8 13 7 3 0 52
Table 2. Differences in Gleason scores (GSs) between biopsy (Bx) and radical prostatectomy (RP) specimens
No difference Downgrade Upgrade
GS difference (RP – Bx) 0 1 2 3 –1 –2
n (%) 16 (31) 9 (17) 8 (15) 4 (8) 8 (15) 7 (13)
Table 3. Correlations of biopsy-core number, biopsy-core length, prostate volume, and preoperative serum prostate-specific
antigen (PSA) level, with differences between Gleason scores obtained from biopsy and radical prostatectomy specimens
Number of cases
No difference Downgrade Upgrade
n (%) n (%) n (%)
Biopsy-core
n Length (mm)
6 < 15 12 1 (8) 8 (67) 3 (25)
> 15 12 6 (50) 3 (25) 3 (25) p = 0.05*
Total 24 7 (29) 11 (50) 6 (21)
10 or 12 < 15 12 2 (17) 6 (50) 4 (33)
> 15 8 4 (50) 1 (12) 3 (38) p = 0.15*
Total 20 6 (30) 7 (35) 7 (35) p = 0.71*
Prostate volume (mL)
10–19 9 2 (22) 4 (45) 3 (33)
20–29 13 5 (38) 5 (38) 3 (22)
30–39 12 4 (33) 7 (59) 1 (8)
40–49 3 0 (0) 1 (33) 2 (67)
50–59 7 2 (29) 2 (29) 3 (42) p = 0.41†
PSA (ng/mL)
0–9 17 8 (47) 4 (24) 5 (29)
10–19 14 3 (21) 8 (57) 3 (21)
20–29 9 1 (11) 5 (56) 3 (33)
30–39 3 1 (33) 1 (33) 1 (33)
40–49 1 0 (0) 1 (100) 0 (0) p = 0.27†
*Fisher’s exact test; †univariate analysis.
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ume ranged from 25.70–94.24 mL (mean, 49.51
mL). One patient underwent prostate sextant biopsy
before October 2002. The others underwent either
10- or 12-core prostate biopsies after October 2002.
Discussion
This study found that the accuracy of Gleason scores
for needle-biopsy specimens of the prostate was only
31%. King and Long10 pooled data from 10 studies
(n = 2,687) and found that such accuracy was 42%
(range, 28–58%). They suggested that a methodology
using more biopsy cores, combined with consensus in
pathologic evaluation, could improve Gleason-score
accuracy. However, Thickman et al13 concluded that
6 biopsy cores were optimal for achieving maximum
Gleason-score accuracy, and in the present study,
more than 6 biopsy-core specimens did not increase
such accuracy.
Bostwick14 reported that Gleason scores for pros-
tate needle biopsy specimens taken with an 18-gauge
needle from 316 patients were only 35% accurate.
He did not find any correlation between the error in
biopsy Gleason score and prostate volume, prostate
weight, or preoperative serum PSA level. In our study,
we also found that prostate volume, prostate weight
and preoperative serum PSA levels were not linked to
the accuracy of Gleason scores for needle-biopsy
specimens.
Although all biopsy needles in this study were 18-
gauge and had a set length of 22 mm, not all biopsy
specimens were the same length. In specimens taken
by sextant biopsy, the accuracy of Gleason scores
increased when biopsy specimens were > 15 mm in
length. However, this correlation was not evident in
specimens taken by the 10- or 12-needle biopsy
procedure. Ruijter et al15 suggested that at least 6
biopsy specimens, each measuring 15 mm in length,
should be obtained to minimize grading error. Some
investigators have suggested that Gleason scores for
samples taken with a 14-gauge biopsy needle are
more accurate than scores for samples taken with an
18-gauge needle.16–19 However, other authors have
reported that Gleason scores for samples taken with an
18-gauge needle are just as accurate as those for
samples taken with a 14-gauge needle.13,14,20 Adequate
biopsy tissue for interpretation increases the accuracy
of Gleason scores for needle-biopsy specimens.
Gleason scores for 4 specimens obtained by
prostatectomy were 3 units greater than correspond-
ing scores for biopsy specimens taken from the same
individuals: 3 of the biopsy specimens had a Gleason
score of 2 + 2, and 1 specimen had a score of 2 + 3.
However, after analyzing specimens from all 52 pa-
tients, we found no correlation between the initial bi-
opsy Gleason score and biopsy-core number, accurate
biopsy-core length, prostate volume, or preoperative
serum PSA level. One of the patients had a very large
prostate (94.24 mL) and only underwent sextant
biopsy. The other 3 patients underwent either 10- or
12-core biopsy, but the biopsy-core lengths were < 15
mm. The sampling error in these cases may have been
due to grading error.
Although the histologic grade of needle-biopsy
specimens is frequently used in clinical decision-
making, the reliability of needle-biopsy Gleason score
is low.13,14,21,22 King23 suggested that, given the clinical
implications of Gleason scores, the staging of organ-
confined prostate cancer should include the likeli-
hood of histologic upgrading when Gleason scores
are used in the following settings: (1) stratification of
patients for clinical trials; (2) comparison of results
for specific therapies based on biopsy grading; (3)
the use of “look-up” tables or formulae to predict
risks for upgrading; and (4) the recommendation of
radical therapy.
The accuracy of Gleason scores for needle-biopsy
specimens in our study was 31%. No correlation between
biopsy Gleason-score error and biopsy number, prostate
Table 4. Data from 4 cases in which radical prostatectomy (RP) Gleason score (GS) was 3 units greater than the
corresponding biopsy (Bx) GS
Number of Bx Bx-core PSA Prostate
cores length (mm) (ng/mL)  volume (mL)
Bx GS RP GS
Case 1 6 > 15 10.22 94.24 2 + 2 4 + 3
Case 2 10 < 15 5.76 28.10 2 + 2 3 + 4
Case 3 10 < 15 12.00 25.70 2 + 2 2 + 5
Case 4 12 < 15 11.55 50.00 2 + 3 3 + 5
PSA = prostate-specific antigen.
Gleason score from prostate biopsy
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volume, or preoperative serum PSA level was noted. In
conclusion, adequate tissue in biopsy cores is important
for accurate tumor grading, and treatment options for
prostate cancer should not be based entirely on Gleason
scores for needle-biopsy specimens.
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